NCT02834403View on ClinicalTrials.gov

L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

January 31, 2021

Study Completion Date

January 31, 2021

Conditions
Metastatic Triple Negative Breast Cancer
Interventions
DRUG

L-NMMA

Nitric oxide synthase inhibitor

DRUG

Docetaxel

Mitotic inhibitor, cytotoxic

DRUG

Amlodipine

Long-acting calcium channel blocker

DRUG

Pegfilgrastim

Colony-stimulating factor

DRUG

Enteric-coated aspirin

non-steroidal anti-inflammatory drug

Trial Locations (1)

77030

Houston Methodist Hospital, Houston

All Listed Sponsors
lead

The Methodist Hospital Research Institute

OTHER

NCT02834403 - L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients | Biotech Hunter | Biotech Hunter